QNTM

Quantum Biopharma Ltd. Class B Subordinate Voting Shares

17.06 USD
-2.10
10.96%
At close Jul 3, 4:00 PM EDT
After hours
17.32
+0.26
1.52%
1 day
-10.96%
5 days
-17.38%
1 month
10.35%
3 months
117.05%
6 months
325.44%
Year to date
318.14%
1 year
84.63%
5 years
-92.83%
10 years
-96.54%
 

About: Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.

Employees: 7

0
Funds holding %
of 7,310 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

116% more capital invested

Capital invested by funds: $256K [Q4 2024] → $553K (+$296K) [Q1 2025]

56% more funds holding

Funds holding: 9 [Q4 2024] → 14 (+5) [Q1 2025]

0.01% more ownership

Funds ownership: 3.63% [Q4 2024] → 3.64% (+0.01%) [Q1 2025]

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Research analyst outlook

We haven’t received any recent analyst ratings for QNTM.

Financial journalist opinion

Based on 5 articles about QNTM published over the past 30 days

Neutral
GlobeNewsWire
1 week ago
Quantum BioPharma Announces Private Placement
TORONTO, June 27, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that it is completing a non-brokered private placement of class A multiple voting shares (“MVS”) at a price of $50 per MVS, for aggregate gross proceeds of up to $600 (the “Offering”). The Company expects that the entirety of the Offering will be subscribed for by the existing holders of MVS.
Quantum BioPharma Announces Private Placement
Neutral
GlobeNewsWire
1 week ago
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering
Engages leading marketing firm MZ Digital and crowdfunding platform Dealmaker to successfully execute raise Engages leading marketing firm MZ Digital and crowdfunding platform Dealmaker to successfully execute raise
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering
Neutral
Newsfile Corp
2 weeks ago
Singular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline Progress
Los Angeles, California--(Newsfile Corp. - June 18, 2025) - Singular Research, a leading provider of independent research on small-cap companies, today released its analysis of Quantum BioPharma Ltd.'s (NASDAQ: QNTM) continued progress across its innovative pipeline of treatments for brain disorders and alcohol health.
Singular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline Progress
Neutral
GlobeNewsWire
2 weeks ago
Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital
Joint Clinical Study with Massachusetts General Hospital Could Pave the Way for Testing Efficacy of Quantum's Investigational MS drug, Lucid-21-302 Joint Clinical Study with Massachusetts General Hospital Could Pave the Way for Testing Efficacy of Quantum's Investigational MS drug, Lucid-21-302
Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital
Neutral
GlobeNewsWire
3 weeks ago
Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds
TORONTO, June 13, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce its intention to declare a special dividend consisting of Contingent Value Rights (the “CVRs”) to be issued on a 1:1 basis to holders of the Company's Class B Subordinate Voting Shares.
Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds
Neutral
GlobeNewsWire
1 month ago
Quantum BioPharma Clarifies It Has Not Changed Its Name
TORONTO, June 03, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces its response to information about certain stock trading platforms as well as misinformation being circulated on certain social media channels. Certain stock trading platforms mistakenly have the Quantum BioPharma name changed to Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.) after the news release was issued on May 29, 2025. Quantum BioPharma has not changed its name.
Quantum BioPharma Clarifies It Has Not Changed Its Name
Neutral
GlobeNewsWire
1 month ago
iNGENū CRO Partners with Quantum BioPharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS Patients
Study Aims to Expedite Potentially Transformative Therapies By Assessing Safety and Efficacy of FSD202 Study Aims to Expedite Potentially Transformative Therapies By Assessing Safety and Efficacy of FSD202
iNGENū CRO Partners with Quantum BioPharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS Patients
Neutral
GlobeNewsWire
1 month ago
Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari
Dr. Raza Bokhari, Company's Former CEO, Paid $2.35 Million USD in Non-Dilutive Cash to Cover Legal and Other Costs Determined in the Arbitral Award Over the Past 4 Years Dr. Raza Bokhari, Company's Former CEO, Paid $2.35 Million USD in Non-Dilutive Cash to Cover Legal and Other Costs Determined in the Arbitral Award Over the Past 4 Years
Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari
Neutral
GlobeNewsWire
1 month ago
Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.
TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.) (the “Company”), the company behind unbuzzdTM, the scientifically-proven beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms, that it has hired leading audit firm MNP LLP (“MNP”) effective May 20, 2025, to conduct Public Company Accounting Oversight Board (“PCAOB”) audits of the Company's financial statements in preparation for a possible initial public offering (“IPO”). The Company's predecessor auditor, Stern & Lovrics LLP (the “Predecessor Auditor”) resigned effective May 20, 2025, at the Company's request, and the Company's board of directors, upon the audit committee's recommendation, appointed MNP to fill the resulting vacancy until the close of the next annual meeting of the Company's shareholders.
Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.
Neutral
GlobeNewsWire
1 month ago
Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome
TORONTO, May 28, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary, FSD Pharma Australia Pty Ltd., that it has received approval by the human ethics review committee (HREC) in Australia for its trial entitled “A Randomized, Double-Blind Placebo Controlled Parallel Group Decentralized Trial to Assess the Safety and Efficacy of FSD202 in Participants with Chronic Widespread Musculoskeletal Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome (Disorder).”
Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome
Charts implemented using Lightweight Charts™